Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for the Iomab-B BLA [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].